SABS
SAB Biotherapeutics Inc
3.10$
+4.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -75.9% | +209.7% | -72.1% | -100.2% | – | -100.0% | – | – | – | – | – | – | |
| – | -4.2% | +110.2% | -48.5% | -5.4% | -18.7% | +874.6% | -89.3% | -6.9% | -0.3% | -1.4% | – | – | |
| – | -326.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | +6.9% | +89.1% | -16.3% | +15.2% | -2.6% | +0.4% | -8.6% | +27.9% | +19.9% | +24.7% | +20.9% | – | |
| – | +478.8% | -71.9% | -13.0% | -4.5% | -23.2% | +16.6% | -12.2% | +35.6% | +35.9% | +30.9% | +9.2% | – | |
| – | +225.3% | -43.2% | -8.8% | +9.5% | -9.7% | -66.6% | +186.1% | +33.7% | +26.0% | +28.2% | +21.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +11.7% | -1.9% | +21.9% | -16.2% | -9.2% | -1.8% | -7.5% | -32.7% | +46.6% | -1.1% | -1.2% | – | |
| – | – | – | – | – | – | – | – | – | -137.1% | – | – | – | |
| – | -100.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -137.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | -134.7% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.